Boothbay Fund Management’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-116,674
Closed -$1.65M 1753
2024
Q2
$1.65M Sell
116,674
-35,670
-23% -$482K 0.04% 565
2024
Q1
$2.08M Hold
152,344
0.04% 493
2023
Q4
$2.05M Buy
152,344
+5,175
+4% +$63.7K 0.05% 477
2023
Q3
$1.84M Buy
147,169
+101,200
+220% +$1.33M 0.04% 529
2023
Q2
$622K Buy
+45,969
New +$634K 0.01% 1007

Other funds holding HQL

Boothbay Fund Management's HQL Position: Q3 2024 in Review

Boothbay Fund Management sold out of abrdn Life Sciences Investors (HQL) in Q3 2024, closing a stake of 116,674 shares — an estimated $1.65M sold.

Boothbay Fund Management first reported a position in HQL in Q2 2023 and held it in 5 quarters. The position peaked at $2.08M in Q1 2024. 74 funds tracked by Wall St. Rank hold HQL as of Q3 2024.

  • Boothbay Fund Management reported no remaining abrdn Life Sciences Investors position as of Q3 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 116,674 abrdn Life Sciences Investors shares in Q3 2024, an estimated $1.65M.
  • Boothbay Fund Management first reported a position in abrdn Life Sciences Investors in Q2 2023 and held it in 5 quarters.
  • Boothbay Fund Management's abrdn Life Sciences Investors position peaked at $2.08M in Q1 2024.
  • 74 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2024.

Based on Boothbay Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.